Expert Interview
What Can Investors Expect from Ultragenyx's rhGUS Phase 3 Data for Patients with MPS7 Coming Mid 2016?
Ticker(s): RAREAn endocrinologist familiar with MPS7 and the rhGUS trial.
MPS7 sounds like an incredibly rare disease. Have you ever had a patient with MPS7? Do you think the disease could be under-diagnosed in the wider population?
Added By: kcmckeeWhat are your thoughts on the rhGUS data thus far?
Added By: kcmckeeDo you think rhGUS will achieve Orphan Drug Status based on the rarity of the disease and lack of current treatments?
Added By: kcmckeeAre there any other treatments on the market or coming through other pipelines of which you are aware?
Added By: kcmckeeCould this type of delivery method be used to address other types of MPS?
Added By: kcmckeeAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Ultragenyx's rhGUS Phase 3 Data for Patients with MPS7 Due Mid 2016 RARE Occurred On: Jul 14, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
